The intravenous bolus injection of FR139317 (10mgkg-') produced a slight decrease in blood pressure in the control rats and in the DOCA-salt hypertensive rat, FR139317 had a more pronounced hypotensive effect. 6 We propose that ET-1 production in vascular tissues is increased in DOCA-salt hypertensive rats. In addition, our study indicates the pathophysiological importance of increased endogenous ET-1 in the maintenance of DOCA-salt-induced hypertension, through interaction of the peptide with ETA receptors.
Introduction
Endothelin-l (ET-1) is the most potent endogenous vasoconstrictor substance so far identified (Yanagisawa et al., 1988) . This peptide possesses a wide variety of biological actions (Rubanyi & Botelho, 1991) and may play a role in the various cardiovascular disorders such as cerebral vasospasm after subarachnoid haemorrhage (Matsumura et al., 1991) , acute renal failure (Kon & Badr 1991) , heart failure (Margulies et al., 1990) , atherosclerosis (Lerman et al., 1991) and hypertension (Vanhoutte, 1993; Liischer et al., 1993) . Circulating ET-1 concentrations are increased during hypertension (Kohno et al., 1991; Widimsky et al., 1991) . However, circulating ET-1 levels do not reflect the local production of the peptide. Indeed, the change in ET-1 content of tissues occurs without change in circulating ET-1 levels (Hughes et al., 1992; Lariviere et al., 1993) .
One study found that there was an increased vascular content of ET-1, with no change in circulating ET-1 concentrations in deoxycorticosterone acetate (DOCA)-salt hypertensive rats (Lariviere et al., 1993) . It has also been reported that renal ET-1 production is altered in spontaneous hypertensive rats (Kitamura et al., 1989; Hughes et al., 1992) . Thus, these changes in local ET-l production might participate in the development and/or the maintenance of hypertension in these models. However, the functional significance of increased or decreased local ET-1 levels in these hypertensive models remains obscure.
Several ET receptor antagonists have been developed and may be useful for evaluating physiological or pathophysiological roles of endogenous ET-1 and its receptor subtypes ' Author for correspondence. (Ihara et al., 1992; Clozel et al., 1993; Sogabe et al., 1993) .
ETA receptor antagonist which inhibits ET-l-induced vasoconstrictor effects in vitro and in vivo Phanmwlogy (1995) 114. [925] [926] [927] [928] [929] [930] (chloroform/methanol, 2:1, including 1 mM N-ethylmaleimide). The homogenates were left overnight at 4°C, then 0.4 vol distilled water was added to the homogenates. In case of extraction from the aorta, thoracic aortae (4 cm) were removed from animals, rapidly cleaned of fat and adherent connective tissue, weighed and homogenized for 60 s in 4 ml ice-cold organic solution, as described above. The homogenates were left overnight at 4°C, then 0.4 ml of distilled water was added to the homogenate. Those aortic or renal homogenates were then centrifuged at 3000 r.p.m. for 30 min and the supernatant was stored. Aliquots of the supernatant were diluted 1/10 with a 0.09% trifluoroacetic acid (TFA) solution and applied to Sep-Pak C1 8 cartridges.
The sample was eluted with 3 ml of 63.6% acetonitrile and 0.1% TFA. Eluates were dried in a centrifugal concentrator and the dried residue was reconstituted in assay buffer for radioimmunoassay (RIA). The clear solution was subjected to RIA. Recoveries of ET-1 from aorta and renal tissues in our extraction procedures were approximately 80%. RIA for ET-1 was carried out as described elsewhere (Matsumura et al., 1990b) . The limit of detection of ET-1 in this assay was 3 pg/tube. ET-1 antiserum (a generous gift from Dr Marvin R. Brown, Department of Medicine, University of California, San Diego, U.S.A.) did not cross-react with big ET-1, as described (Hexum et al., 1990 ).
Reverse-phase high-performance liquid chromatography After application of the tissue sample to a Sep-Pak C18 cartridge, the dried residue was dissolved in 0.5 ml of 0.02% TFA instead of radioimmunoassay buffer and a 0.4 ml portion was then applied to a Capcell-Pak C18-SG300 column (4.6 x 250 mm, Shiseido, Tokyo, Japan), using a highperformance liquid chromatography (h.p. Ltd., Osaka, Japan. FR139317 was dissolved in 1 N NaOH and diluted with saline. Other chemicals were purchased from Nacalai Tesque, Inc (Kyoto, Japan). Table 1 summarizes the comparative data on groups of animals treated with DOCA-salt for 7 or 28 days and of age-matched controls. There were no differences in systolic blood pressure of the control animals and those treated with DOCA-salt for 7 days. After 28 days of DOCA-salt treatment, systolic blood pressure was significantly elevated, compared with control animals (116 vs 187 mmHg). The increase in body weight of DOCA-salt rats was smaller than that in control rats. A significant difference between control and DOCA-salt rats with respect to aortic weight was seen at 28 days.
Results
Figure la shows the change in aortic IR-ET concentrations in control and DOCA-salt rats. After 7 days of DOCA-salt treatment, a slight increase in aortic IR-ET content was observed compared with age-matched control rats. However, this increase was not statistically significant. After 28 days of DOCA-salt treatment, aortic IR-ET content was significantly higher than in the aged-matched control (2.23 ± 0.37 and 0.93 ± 0.10 ng g-aortic tissue). On the other hand, no significant changes occurred in renal IR-ET contents of the two experimental groups at 7 and 28 days (control rats; 0.20 ± 0.04 and 0.14 ± 0.01 ng g' tissue at 7 and 28 days, respectively vs DOCA-salt rats; 0.17 ± 0.02 and 0.13 ± 0.01 ng g' tissue at 7 and 28 days, respectively, Figure   lb ). There was a positive correlation between systolic blood pressure and aortic IR-ET content in the DOCA-salt animals ( Figure 2) .
The dilution curve of aortic extract clearly revealed a parallel displacement with the standard curve (Figure 3a) . To 
Discussion
The results of the present study clearly demonstrated increased vascular endothelin-I concentrations in DOCA-salt hypertensive rat. The ETA receptor antagonist, FR139317, produced a significant decrease in MAP in these DOCA-salt hypertensive rats. As this hypotensive effect was greater than that seen with control rats, the specificity of the finding in DOCA-salt hypertensive rats seem clear. It is most likely that ET-1 makes an important contribution to the maintenance of DOCA-salt-induced hypertension through interaction of the peptide with the ETA receptor.
We observed an increase aortic ET-1 concentration in association with the hypertension induced by DOCA-salt treatment. Since circulation ET-1 concentrations were not increased in DOCA-salt hypertensive rats, except for the malignant model (Suzuki et al., 1990; Kohno et al., 1991) The question arises as to whether the increase in aortic ET-1 levels in DOCA-salt hypertensive rats is merely the result of hypertension. From our results, the possibility that hypertension itself can induce the vascular ET-1 production cannot be ruled out. However, Lariviere et al. (1993) noted that vascular ET-1 was not increased in spontaneous hypertensive rats, thereby suggesting that hypertension itself does not enhance ET-1 production in vascular tissues.
There is considerable evidence that many factors, including transforming growth factor-pi (TGF-p,) , thrombin, and a vasoactive agent such as angiotensin II and argininevasopressin (AVP) can stimulate the expression of prepro ET-1 mRNA in cultured endothelial cells (Kurihara et al., 1989; Imai et al., 1992; Umekawa et al., 1994) . It has been reported that AVP plays an important role in DOCA-salt hypertensive rats (Crofton et al., 1979) . Mohring et al. (1977) observed that plasma concentrations of AVP were elevated in this model of hypertension. Thus, AVP may be one possible candidate for the factor that enhances ET-1 production in the vascular wall. In a study by Sarzani et al. (1989) , aortic TGF-P, mRNA levels were increased in DOCA-salt rats; this growth factor may also be responsible for the increased aortic ET-1 concentrations.
Several ET receptor antagonists have been developed and these will be used to evaluate pathophysiological roles of endogenous ET-1 and may provide a new therapeutic approach for cardiovascular diseases. FR139317 is a selective ETA receptor antagonist which inhibits ET-1-induced vasoconstrictor effects in vitro and in vivo (Sagabe et al., 1993) . This antagonist ameliorates cerebral vasospasm after subarachnoid haemorrhage . It has also been reported that FR139317 can protect against the injury in rats with extensive renal mass reduction, a model of progressive renal disease (Benigni et al., 1993) . These results demonstrate the efficacy of FR139317 as an ETA receptor antagonist for investigating the pathophysiological role of ET-1. In the present study, to clarify further the functional significance of increased vascular ET-1 levels, we evaluated the antihypertensive effect of FR139317 in DOCA-salt hypertensive rats. The result clearly indicated that FR139317 produced a significant hypotensive effect in anaesthetized DOCA-salt hypertensive rats. This hypotensive effect had a slow-onset and was long lasting, a finding consistent with a study which showed that the slow reversal of the vasoconstrictor effects of ET-1 is caused by another ETA receptor antagonist, BQ123, in vitro and in vivo (Warner et al., 1994) . These authors observed that it takes about 50min for the antagonist to reverse the established pressor response to ET-1 in anaesthetized rats.
Our results obtained with anaesthetized DOCA-salt hypertensive rats agreed with the finding that another ETA receptor antagonist, BQ123, produces a small but significant hypotensive effect in conscious DOCA-salt hypertensive rats (Bazil et al., 1992) . It has been reported that phosphoramidon, an endothelin converting enzyme inhibitor (Matsumura et al., 1990a) , produces a reduction of blood pressure in DOCA-salt hypertensive rats, by inhibiting endothelin bioconversion (Vemulapalli et al., 1993) . Stein et al (1994) reported that the orally active ETA receptor antagonist, 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulphonamide, produced a significant decrease in blood pressure, in DOCA-sa4t hypertensive rats. These results show the importance of ET-1 and the ETA receptor in the maintenance of DOCA-salt induced-hypertension.
In the present study, we observed that FR139317 produced a slight but significant decrease in MAP in control normotensive rats. This would suggest a role of ET-1 and the ETA receptor in the maintenance of normal blood pressure. However, a previous report indicated that an acute bolus injection of FR139317 had no effect on blood pressure in conscious normotensive rats . BQ123 also had no significant effect of blood pressure in conscious normotensive rats (Bazil et al., 1992; Nishikibe et al., 1993) . One explanation for this discrepancy may relate to the experimental condition (anaesthetized rat vs conscious rat). It has been reported that the standard experimental technique such as surgery produces a significant increase in circulating ET-1 . Therefore, circulating ET-1 may be increased in anaesthetized rats. Other investigators reported that BQ123 produced a significant decrease in blood pressure in anaesthetized normotensive rats (Bigaud & Pelton 1992; .
Our conclusions regarding the involvement of ET-1 and ETA receptor in DOCA-salt hypertension depend on the specificity of FR139317 as an ETA receptor antagonist. In the present study, FR139317 reduced MAP in normotensive rats as well as DOCA-salt hypertensive rats, although the reduction of MAP in the former was small, compared with that in the latter. Since any nonspecific depressor agent would be expected to have a greater hypotensive effect in animals with higher resting blood pressure, one may be doubtful of the specificity of FR139317 for DOCA-salt hypertension. However, we noted that FR139317 treatment to anaesthetized 2K-1C renal hypertensive rats produces only a moderate hypotensive effect to the same degree as that in anaesthetized normotensive rats (unpublished observation).-Thus, it seems likely that the greater responses of DOCA-salt hypertensive rats are not due to a nonspecific depressor effect of the agent. In addition, the dose of FR139317 used in our study has been shown to have no effect on the initial depressor response to ET-1, which is mainly mediated by the ETB receptor . It is reasonable to consider that the antihypertensive effect of FR139317 in DOCA-salt hypertensive rat could be due to an ETA receptor antagonism.
In conclusion, our results suggest that there is an increased vascular production of ET-1 in DOCA-salt hypertensive rats. In addition, our results indicate the pathophysiological significance of increased endogenous ET-1 in the maintenance of DOCA-salt induced hypertension, through interaction of this peptide with the ETA receptor. 
